A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy
2026年8月28日 更新者:Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity receiving positive airway pressure (PAP) therapy.
Eligible participants will be screened and randomized to the HDM1005 group or the placebo group at a ratio of 1:1 , HDM1005 or placebo will be given once weekly for 52 weeks, following by a safety follow up of 4 weeks.
All participants received a lifestyle intervention that involved counselling on diet and physical activity.
研究概览
研究类型
介入性
注册 (估计的)
200
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Xueran Li
- 电话号码:0571-89908523
- 邮箱:cxylixueran@eastchinapharm.com
学习地点
-
-
-
Beijing、中国
- Beijing Anzhen Hospital
-
接触:
- Jiang Xie
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Age between 18 and 75 years, male or female, at the time of signing the informed consent form.
- BMI ≥ 28.0 kg/m² at both screening and randomization.
- A self-reported change in body weight no more than 5% within 90 days before screening.
- Subject has been diagnosed with obstructive sleep apnea (OSA) according to the International Classification of Sleep Disorders, 3rd Edition (ICSD-3) criteria prior to screening, and has a centrally assessed apnea-hypopnea index (AHI) ≥15 events/hour on polysomnography (PSG) at screening.
- ≥3 months of PAP therapy pre-screening with planned continuation; willingness to pause PAP ≥1 week before each PSG.
Exclusion Criteria:
- History of any type of diabetes mellitus (history of gestational diabetes is permitted).
- Have obesity induced by other endocrinologic disorders or by other medicine.
- History of thyroid C-cell carcinoma, multiple endocrine neoplasia type 2 (MEN2) or relevant family history.
- Diagnosis of central or mixed sleep apnea or Cheyne-Stokes respiration.
- Respiratory or neuromuscular diseases judged by the investigator to potentially interfere with trial results.
- Clinical abnormalities or diseases related to insomnia or excessive sleepiness (excluding OSA).
- Uncontrolled hypertension prior to screening, defined as: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg (stable for 1 month if using antihypertensive drugs).
- History of malignancy (except cured basal cell carcinoma) in the past 5 years or at the time of screening.
- History of severe cardiovascular or cerebrovascular diseases within the past six months.
- The subject has any other factors that may affect the efficacy or safety evaluation of this study, and is not suitable for participation in this study in the opinion of the investigator.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂
|
起始剂量为每周0.5毫克,并遵循剂量递增方案,每4周增加一次剂量,以达到维持剂量。
干预将持续总共52周。
|
|
实验性的:HDM1005
|
Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Percentage change in body weight from baseline at week 52
大体时间:52 week
|
52 week
|
|
Change in AHI from baseline at week 52
大体时间:52 week
|
52 week
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Percentage change in AHI from baseline
大体时间:52 week
|
52 week
|
|
Proportion of participants with ≥50% reduction in AHI from baseline
大体时间:52 week
|
52 week
|
|
Proportion of participants achieving the following criteria:AHI < 5; or 5 ≤ AHI ≤ 14 and Epworth Sleepiness Scale (ESS) score ≤ 10
大体时间:52 week
|
52 week
|
|
Proportion of subjects whose body weight decreased by ≥ 5%, ≥ 10%, or ≥ 15% relative to baseline
大体时间:52 week
|
52 week
|
|
Change in Epworth Sleepiness Scale (ESS) Score from Baseline at Week 52 of Treatment
大体时间:52 week
|
52 week
|
|
Incidence of adverse events (AEs)
大体时间:52 week
|
52 week
|
|
Proportion of subjects reporting improvement in Patient Global Impression of Severity (PGIS)-OSA categories at Week 52 of treatment
大体时间:52 week
|
52 week
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年9月1日
初级完成 (估计的)
2028年9月1日
研究完成 (估计的)
2028年11月1日
研究注册日期
首次提交
2026年8月25日
首先提交符合 QC 标准的
2026年8月28日
首次发布 (实际的)
2026年8月31日
研究记录更新
最后更新发布 (实际的)
2026年8月31日
上次提交的符合 QC 标准的更新
2026年8月28日
最后验证
2026年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.